Antitumor response (RECIST (version 1.1) scale). Measuring time: 3, 6, 9, 12, 15, 18, 21, 24 months.
Safety
Adverse Events-AE (AE description (Name of the AE), AE Intensity (mild, moderate, severe, life-threatening, death) Causality relationship (very probable, probable, possible, unlikely, not related, not evaluable), Gravity (serious, non serious), Previous knowledge (expected, non expected) Result (recovered, improved, sequelae, death), Treatment (none, medication, surgical procedure, transfusion, other). Measuring time: 3, 6, 9, 12, 15, 18, 21, 24 months.
Immunogenicity
IgM and IgG against NGcGM3 ganglioside (ELISA). Measuring time: At baseline, 85, 169, 337 days.
Recognition and lytic capacity of IgM and IgG antibodies induced by vaccination and directed to NGcGM3 on tumor lines expressing ganglioside (flow cytometry). Measuring time: At baseline, 85, 169, 337 days
peripheral blood cells: CD3+, CD3+/CD4+, CD3+/CD8+, T reguladoras (CD4+/CD25+/Foxp3+), CD19+ (células B), NK (CD3-/CD16+/CD56+/CD69+), NKT (CD3+/CD56+). Flow cytometry. At baseline, months 3, 6 and 9.
Myeloide derived suppressor cells MDSC: (HLADRlow-/LIN-/CD11b+/CD 14+/CD33+).Flow cytometry. At baseline, months 3, 6 and 9.
Anti-HLA-A2: HLA-A2 NY-ESO 1, HLA-A2 Tyrisnase, HLA-A2 GP 100, HLA-A2 Mart-1, HLA-A2 MAGE A1, and MAGE A3 response
Flow cytometry. At baseline, months 3, 6 and 9.
IL-6 y IL-8. ELISA. At baseline, months 3, 6 and 9.